Mersana Therapeutics, Inc. Appoints Donald A. Bergstrom, M.D., Ph.D., And Eva M. Jack To Executive Leadership Positions
Published: Jan 08, 2014
Mersana Therapeutics, a biopharmaceutical company developing its Fleximer® antibody-drug conjugate (ADC) platform and therapeutics, today announced two executive appointments. Donald A. Bergstrom, M.D., Ph.D., has been appointed Chief Medical Officer, adding substantial experience in oncology translational research to Mersana's team. Eva M. Jack has been appointed Mersana's Chief Business Officer, bringing a successful track record in business development and venture capital.
Help employers find you! Check out all the jobs and post your resume.